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PURPOSE: A new human polyomavirus, Merkel cell polyomavirus (MCV), was
identified in 2008 in tumor tissue of patients with Merkel cell carcinoma (MCC), a
relatively rare human skin cancer. In this study, we investigated patients with MCC
and controls for the presence of antibodies against MCV and their association with
clinical characteristics.
PATIENTS AND METHODS: Antibodies against MCV were investigated by enzyme-
linked immunosorbent assay in 68 patients with MCC and 82 controls using VP1
virus-like particles produced in insect cells.
RESULTS: Antibodies against MCV were detected in all patients with MCC and in
85% of controls. However, high antibody titers (> 10,000) were rarely observed in
controls (7.3%) and they were detected in 64.7% of patients with MCC (P < .001) in
contrast to the absence of VP1 expression in tumor samples. In addition, the
geometric mean titer of anti-MCV in patients with MCC was around 14 times higher
than that observed in MCV-positive controls (P < .001) and was not correlated with
tumor viral load. High antibody titers were not found to be associated with any
subject or tumor characteristics, but better progression-free survival was observed
in patients with high antibody titers (hazard ratio, 4.6; 95% CI, 1.7 to 12.2; P =
.002).
CONCLUSION: High titers of MCV antibodies in a much higher proportion of
patients with MCC than in controls confirmed the association between MCV infection
and MCC. The findings also indicated that a better progression-free survival
occurred in patients with high MCV antibody titers and suggested that there are at
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